ImpediMed Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de ImpediMed de 67.5% y 41% por año respectivamente. Se prevé que el BPA crezca en un 80.6% al año. Se espera que la rentabilidad financiera sea de 50.4% en 3 años.

Información clave

67.5%

Tasa de crecimiento de los beneficios

80.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.2%
Tasa de crecimiento de los ingresos	41.0%
Rentabilidad financiera futura	50.4%
Cobertura de analistas	Low
Última actualización	23 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

Previsiones de crecimiento de beneficios e ingresos

ASX:IPD - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2027	40	7	N/A	10	1
6/30/2026	24	-8	-18	-1	2
6/30/2025	15	-15	-18	-12	2
6/30/2024	10	-20	-21	-18	N/A
3/31/2024	10	-20	-19	-15	N/A
12/31/2023	10	-19	-18	-13	N/A
9/30/2023	11	-20	-21	-15	N/A
6/30/2023	11	-21	-24	-18	N/A
3/31/2023	11	-21	-25	-20	N/A
12/31/2022	11	-22	-27	-22	N/A
9/30/2022	11	-21	-24	-19	N/A
6/30/2022	11	-20	-21	-16	N/A
3/31/2022	10	-20	-19	-14	N/A
12/31/2021	10	-19	-17	-13	N/A
9/30/2021	9	-20	-16	-13	N/A
6/30/2021	8	-21	-16	-13	N/A
3/31/2021	7	-20	-17	-15	N/A
12/31/2020	6	-19	-18	-16	N/A
9/30/2020	6	-20	-20	-18	N/A
6/30/2020	6	-21	-21	-19	N/A
12/31/2019	5	-25	-22	-20	N/A
9/30/2019	5	-24	-22	-20	N/A
6/30/2019	4	-24	-22	-20	N/A
12/31/2018	4	-25	-23	-21	N/A
9/30/2018	3	-26	-24	-22	N/A
6/30/2018	3	-27	-25	-23	N/A
3/31/2018	4	-28	N/A	N/A	N/A
12/31/2017	4	-28	N/A	-26	N/A
9/30/2017	5	-28	N/A	-26	N/A
6/30/2017	6	-28	N/A	-26	N/A
3/31/2017	6	-28	N/A	-25	N/A
12/31/2016	6	-29	N/A	-25	N/A
9/30/2016	6	-27	N/A	-24	N/A
6/30/2016	6	-26	N/A	-22	N/A
3/31/2016	6	-23	N/A	-19	N/A
12/31/2015	5	-20	N/A	-16	N/A
9/30/2015	5	-17	N/A	-13	N/A
6/30/2015	5	-15	N/A	-11	N/A
3/31/2015	4	-13	N/A	-9	N/A
12/31/2014	4	-10	N/A	-8	N/A
9/30/2014	4	-9	N/A	-7	N/A
6/30/2014	4	-8	N/A	-7	N/A
3/31/2014	3	-7	N/A	-6	N/A
12/31/2013	3	-7	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que IPD sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que IPD sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que IPD sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (41% al año) de IPD crezcan más rápidamente que los del mercado Australian (5.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (41% al año) de IPD crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de IPD sea muy elevada dentro de 3 años (50.4%).

ImpediMed Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 8.8% to AU$0.15

Consensus revenue estimates decrease by 14%

Forecast to breakeven in 2027

Forecast to breakeven in 2026

Price target decreased by 9.6% to AU$0.18

Consensus revenue estimates decrease by 13%

Recent updates

ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024

ImpediMed Limited, Annual General Meeting, Nov 19, 2024

Price target decreased by 8.8% to AU$0.15

Consensus revenue estimates decrease by 14%

Board Member recently bought AU$73k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2027

ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Forecast to breakeven in 2026

ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes